SAN DIEGO, Oct. 26, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Second Quarter Fiscal 2016 investor conference call and webcast on Monday, November 16, 2015 at 4:30 p.m. Eastern Time.
The call and webcast will follow the release of fiscal 2016 second quarter results. A recorded version of the call will be available approximately two hours after the call at the Investor Relations portion of the company's website, www.aethlonmedical.com.
Interested parties can also access the archived replay of Aethlon Medical's First Quarter Fiscal 2016 investor conference call webcast at www.aethlonmedical.com in the investor relations section under events & presentations.
Conference Call Details
What: Aethlon's Second Quarter Fiscal 2016 Investor Conference Call and Webcast
Date: Monday, November 16, 2015
Time: 4:30 p.m. Eastern Time
Live call: 412-902-6510
Audio Replay: 412-317-0088
About Aethlon Medical, Inc.
Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.
James A. Joyce Chairman and CEO (Office) 858.459.7800 x301 (Cell) 619-368-2000 email@example.com
Jim Frakes Chief Financial Officer 858.459.7800 x300 firstname.lastname@example.org
Mike Smargiassi/Brad Edwards Brainerd Communicators, Inc 212-986-6667 email@example.com
SOURCE Aethlon Medical, Inc.